Efficacy of CBD-enriched medical cannabis for treatment of refractory epilepsy in children and adolescents – An observational, longitudinal study

Moran Hausman-Kedem*, Shay Menascu, Uri Kramer

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

The objective of this observational study was to evaluate the efficacy of medical cannabis for the treatment of refractory epilepsy. Fifty-seven patients (age 1–20 years) with epilepsy of various etiologies were treated with Cannabis oil extract (CBD/THC ratio of 20:1) for at least 3 months (Median follow up time-18 months). Forty-Six Patients were included in the efficacy analysis. Average CBD dose was11.4 mg/kg/d. Twenty-six patients (56%) had ≤50% reduction in mean monthly seizure frequency. There was no statistically significant difference in response rate among various epilepsy etiologies, and cannabis strain used. Younger age at treatment onset (<10 years) and higher CBD dose (>11 mg/kg/d) were associated with better response to treatment. Adverse reactions were reported in 46% of patients and were the main reason for treatment cessation. Our results suggest that adding CBD-enriched cannabis extract to the treatment regimen of patients with refractory epilepsy may result in a significant reduction in seizure frequency according to parental reports. Randomized controlled trials are necessary to assess its true efficacy.

Original languageEnglish
Pages (from-to)544-551
Number of pages8
JournalBrain and Development
Volume40
Issue number7
DOIs
StatePublished - Aug 2018

Keywords

  • Anti-seizure drugs
  • Antiepileptic drugs
  • CBD-enriched cannabis extract
  • Cannabidiol
  • Cannabis
  • Efficacy
  • Refractory epilepsy
  • Seizures

Fingerprint

Dive into the research topics of 'Efficacy of CBD-enriched medical cannabis for treatment of refractory epilepsy in children and adolescents – An observational, longitudinal study'. Together they form a unique fingerprint.

Cite this